Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nipro Files for Full Approval of Stemirac Cell Therapy
Nipro said on November 17 that it has filed for full approval of Stemirac, the first stem cell therapy for spinal cord injuries conditionally approved in Japan in late 2018. The application seeks the nod for Stemirac as a new…
To read the full story
Related Article
- Nipro Launches Stemirac Manufacturing Facility in Tokyo
June 8, 2020
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- MHLW Acknowledges Need to Ponder Rules for “Regenerative Medicines”: Official
February 21, 2019
- Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
BUSINESS
- Japan Pharma Market Grows 3.8% in FY2025 as Protected Brands Shine: IQVIA
July 13, 2026
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…